Complement Regulation and Unmet Needs in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Speakers: Satheesh Chonat, MD, Assistant Professor, Pediatric HematologyCarlos de Castro, MD, Professor of Medicine, Division of Hematologic Malignancies & Cell Therapy
Duration: 90 minutes
Presented on: May 26, 2022
Satheesh Chonat, MD
Satheesh Chonat, MD
Assistant Professor, Pediatric HematologySatheesh Chonat, MD, is a board-certified Pediatric Hematologist/Oncologist at Children’s Healthcare of Atlanta and an Assistant Professor of Pediatrics at Emory University School of Medicine. Dr. Chonat specializes in the care of children and young adults with nonmalignant rare blood disorders and has a research focus on rare anemias and complement disorders. He is particularly interested in leveraging pre-clinical animal models and translational research to explore the mechanisms underlying hemolytic anemias and thrombotic microangiopathies, investigate biomarkers for diagnostic testing, and develop newer therapies. Dr. Chonat is also the site investigator for various clinical and translational research projects, focused on rare red blood disorders, such as pyruvate kinase disease.
Carlos de Castro, MD
Carlos de Castro, MD
Professor of Medicine, Division of Hematologic Malignancies & Cell TherapyCarlos de Castro, MD, is a Professor of Medicine at Duke University in the Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine and a member of the Duke Cancer Institute. His clinical research focuses on treatments for bone marrow failure conditions such as paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia, myelodysplastic syndromes, and acute leukemias. Dr. de Castro has served in several roles at Duke including Medical Director of the 9100 Malignant Hematology Ward, Medical Director of the Apheresis Unit, and Program Director of the Duke Hematology-Oncology Fellowship Program. He is on the NCCN panel for Myelodysplastic Disorders and serves as a member of the Medical Board of Directors for the Aplastic Anemia & MDS International Foundation.
CME InformationComplement Regulation and Unmet Needs in the Treatment of Paroxysmal Nocturnal HemoglobinuriaThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Aplastic Anemia and MDS International Foundation (AAMDS), and National Organization for Rare Disorders (NORD)
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Apellis Pharmaceuticals Inc.
LIVE RELEASE DATEThursday, May 26 from 10:00 AM-11:30 AM ET.
TARGET AUDIENCEThe target audiences for the proposed HCP activity are Community-based and academic hematologists, medical oncologists, hematologic oncologists, pathologists, primary care providers, nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.
STATEMENT OF NEED/PROGRAM OVERVIEWQuality of life for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) could be greatly improved with faster diagnoses, appropriate treatments, and management of a plethora of challenges that persist despite therapy. A low index of suspicion for PNH and a lack of familiarity with diagnostic criteria often lead to lengthy delays in diagnoses and a lack of treatment for patients. In addition, recent advances in therapeutic options and issues of convenience related to complement-regulating therapies for PNH make it difficult to select the most appropriate treatment for each patient.
Join hematology experts Dr. Carlos de Castro and Dr. Satheesh Chonat to explore strategies to identify and diagnose PNH earlier in the disease course. Patient case studies will help clinicians select the most appropriate treatment for complement regulation and address the significant health burdens and disease complications experienced by many patients during treatment. In addition, panelists will discuss special patient circumstances that may require additional counseling or guidance to available resources.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Describe strategies to decrease delays in the diagnosis of PNH
- Review existing and emerging therapeutic agents for PNH that target the complement cascade
- Discuss management of persistent challenges experienced by patients with PNH that impact quality of life
- Identify special circumstances that require counseling of patients with PNH
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 90 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Dr. Satheeth Chonat, M.D
Assistant Professor, Pediatric Hematology
Emory University School of Medicine
Children’s Healthcare of Atlanta
Consulting Fee (e.g., Advisory Board): Agios, Alexion, Daichi Sankyo, Forma Therapeutics, Novartis, and Takeda pharmaceuticals
Contracted Research: Agios, Alexion, Amgen, Apellis, Global Blood Therapeutics, Takeda
Dr. Carlos de Castro
Professor of Medicine
Department of Medicine, Division of Hematologic Malignancies & Cell Therapy
Consulting Fee (e.g., Advisory Board): Alexion Pharmaceuticals,Apellis Pharmaceuticals, Biocryst Pharmaceuticals, Novartis Pharmaceuticals
Speakers Bureau: Apellis Pharmaceuticals
Other: Regeneron Pharmaceuticals (Data Safety Monitoring Committee)
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Sumera Ackbarali Nothing to disclose Caroline Laurendeau Nothing to disclose Theresa Elgin-Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.